Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a ...
JP Morgan analyst Samik Chatterjee initiated coverage on Jamf Holding Corp. JAMF with an Overweight rating and announced a ...
Fintel on MSN2d
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform RecommendationFintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...
William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes ...
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on ...
Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the company, Ratings reports ...
This page features the latest news about the Mersana Therapeutics stock. MRSN stock touches 52-week low at $0.56 amid market challenges Mersana Therapeutics Inc . (NASDAQ:MRSN) stock has reached a ...
Bala Mohan, the Senior Vice President and Chief Development Officer at Mersana Therapeutics, Inc. (NASDAQ:MRSN), recently sold shares of the company as per a filing with the Securities and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback